Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175040 | 0.89 | GAA (0.50) | ROCK2GAANAMPT | |
| SCHEMBL6174514 | 0.89 | GAA (0.46) | ROCK2NR1H4GAAEPHX2NAMPT | |
| SCHEMBL6700028 | 0.86 | PIK3CA (0.37) | ROCK2PIK3CAHPGDSNAMPTRORC | |
| SCHEMBL6181335 | 0.85 | NR1H4 (0.47) | NR1H4EPHX2NAMPT | |
| SCHEMBL6176385 | 0.81 | MMP13 (0.46) | NR1H4EPHX2 | |
| SCHEMBL6697241 | 0.77 | LMNA (0.48) | GAANAMPT | |
| SCHEMBL6179339 | 0.76 | GAA (0.43) | ROCK2GAANAMPT | |
| SCHEMBL6177877 | 0.72 | MAPT (0.41) | GAAEPHX2NAMPT | |
| SCHEMBL5697161 | 0.68 | MMP13 (0.43) | — | |
| SCHEMBL5697274 | 0.67 | MMP13 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | ROCK2 47/4885NR1H4 1712/4885PIK3CA 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.